$17.53
4.16% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Mesoblast Limited Sponsored ADR Stock price

$17.53
+5.95 51.38% 1M
+10.68 155.91% 6M
+15.33 696.82% YTD
+15.35 704.13% 1Y
+8.21 88.09% 3Y
+2.73 18.45% 5Y
-18.17 50.90% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.76 4.16%
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Key metrics

Market capitalization $2.01b
Enterprise Value $2.07b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 350.66
P/S ratio (TTM) P/S ratio 341.16
P/B ratio (TTM) P/B ratio 4.16
Revenue growth (TTM) Revenue growth -24.47%
Revenue (TTM) Revenue $5.89m
EBIT (operating result TTM) EBIT $-58.69m
Free Cash Flow (TTM) Free Cash Flow $-55.76m
Cash position $71.32m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 173.51
EV/Sales forward 178.34
Short interest 1.58%
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
67%
Hold
33%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5.89 5.89
24% 24%
100%
- Direct Costs 16 16
43% 43%
266%
-9.79 -9.79
48% 48%
-166%
- Selling and Administrative Expenses 19 19
25% 25%
321%
- Research and Development Expense 25 25
7% 7%
430%
-54 -54
-
-917%
- Depreciation and Amortization 4.66 4.66
-
79%
EBIT (Operating Income) EBIT -59 -59
19% 19%
-997%
Net Profit -88 -88
7% 7%
-1,489%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
10 days ago
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. RYONCIL is the only MSC therapy approved in the U.S. for any indication, a...
Positive
Investors Business Daily
10 days ago
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.
Positive
Reuters
10 days ago
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today